ClinicalTrials.gg
RecruitingNCT07022418Updated Feb 5, 2026

Formoterol in Diabetes

A Phase 2 interventional study of Formoterol furmarate (20 μg) in Diabetic Nephropathies and Diabetic Kidney Disease, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Medical University of South Carolina · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Planned enrollment
47th of 120
120 · median 79
Started
2025
with 5 others
Phase 2
54 of 153
5 open now
Primary completion
2026-12
later than 10 of 30 live
Registered
147th of 153
by date

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 47th largest by planned enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2025, is one of 54 in phase 2, reaches primary completion later than 10 of the 30 other live ones, and was the 147th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of not receiving formoterol fumarate. Both groups will continue their standard of care treatment during the study. The primary goal is to gather data on feasibility and effect sizes to properly power a future clinical trial.

Read the detailed description

Glomerular function is highly dependent on specialized cells known as podocytes, which are critical components of glomeruli. Diseases affecting podocytes and the glomerulus, such as diabetes, are the leading causes of ESKD, and there are no specific therapies that restore injury-induced loss of podocyte structure and function. It was previously shown using mouse models of podocyte injury that formoterol fumarate, a long-acting β2-AR agonist given four hours following injury, when glomerular dysfunction is already established, restored glomerular structure, significantly reduced proteinuria, and accelerated recovery of glomerular function. To determine if a similar effect occurred in CKD, specifically DN, investigators used streptozotocin, a murine model of type 1 diabetes, and a high fat diet (HFD), a murine model of type 2 diabetes, to examine the role of formoterol fumarate in DN. Following formoterol fumarate treatment, there was a marked recovery from and reversal of DN in the streptozotocin and HFD mice treated with formoterol fumarate compared to those treated with vehicle alone at the ultrastructural, histological, and functional levels. Investigators also performed a competing risk regression in Veterans aged 65 or over with incident CKD stage 4 to compare the rate of ESKD progression in Veterans without and with COPD, who use β2-AR agonists. Investigators found a 25.6% reduction in the rate of ESKD in Veterans with COPD compared to those without4. In a second cohort of Veterans, Investigators demonstrated significantly slower progression from CKD stage 3 to CKD stage 5 in patients with COPD compared to those without COPD. Together these data indicate that β2-AR agonists, especially formoterol fumarate, may be a novel treatment for DN.

03

Conditions studied

  • Diabetic Nephropathies
  • Diabetic Kidney Disease

Keywords

  • Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-75
  • Diagnosis of type 2 diabetes according to American Diabetes Association (ADA) criteria
  • On stable medical therapy for at least 3 months
  • Stage CKD G2 to G3b; A2-A3 as defined by with no requirement for renal for diagnosis
  • Diabetic kidney disease as per Nephrologist
  • Urinary albumin to creatinine excretion rate (UACR) 200-5000 mg/g/24hrs on at least two occasions (one of these can be a spot UACR)
  • \<8%
  • Receiving stable doses of ACE inhibitor or ARB therapy prior to screening (at least 3 months, unless ) and/or a stable dose of an SGLT inhibitor (at least 3 months preceding enrollment)
  • Receiving stable doses of all additional anti-HTN medications, insulin, oral and injectable non-insulin agents and cholesterol lowering medications at least 3 months prior (unless contraindicated) to randomization and agree to maintain until the study's conclusion.
  • Willing and able to comply with schedule of events and protocol requirements, including written .

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant or breast feeding or who plan on becoming pregnant
  • Currently take beta-agonists
  • Organ transplant recipients
  • Any history of (NYHA) class III/IV heart failure or recent history of serious heart problem (CABG, stroke, MI) in the past 12 months
  • Any history of asthma
  • Patients with serum potassium levels \<3.5 mEQ/L
  • Patients with uncontrolled HTN SBP >150mmHg, DBP >95mmHg
  • showing elongation or tachyarrhythmia; including sinus tachycardia >100bpm
  • to formoterol fumarate (, including patients with known hypersensitivity to ACE inhibitors or ARBs)
  • Advanced organ failure
  • Untreated/uncontrolled cardiovascular, pulmonary, or gastrointestinal disease
  • Patients with >50
  • Active untreated cancer
  • Alcohol or drug abuse in the past 6 months
  • Being involuntarily incarcerated
  • Participating in another interventional study
  • Unable or unwilling to do the 36-week intervention
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    Standard of Care Only

    Standard of Care Treatment Only

  • Experimental
    Formoterol Fumarate + Standard of Care Treatment

    Formoterol Fumarate Inhalation Solution as one 20 mcg unit-dose vial administered twice daily (morning and evening) by nebulization (in addition to standard of care treatment)

    Drug: Formoterol furmarate (20 μg)

Interventions

  • DrugFormoterol furmarate (20 μg)

    Investigators chose to use the long-acting β2-AR agonist, formoterol, because of its efficacy and safety profile in patients with COPD and because formoterol showed the most association with protection from progression of CKD in our retrospective study.

06

What researchers measure

Primary outcomes

  1. Feasibility: refusal rate and adherence during the 36-week treatment

    The primary measures of feasibility will be study refusal rate and adherence during the 36-week treatment. Refusal rate will be the percentage of individuals who are offered the opportunity to enroll but choose not to accept it. Adherence will be defined as the proportion of doses taken during the 36-week treatment period. For patients who fail to complete the study, adherence will be estimated as the number of doses they report taking for visits at which they are present over the total number of doses they should have received.

    Time frame: 36 weeks

  2. To assess the safety, tolerability, and acceptability of the intervention with formoterol

    Rates of adverse events and safety measures will be compared between groups. The investigators will assess adherence with the intervention and study medication.

    Time frame: 36 Weeks

  3. To perform preliminary efficacy testing and determine the variability of albuminuria

    Changes in albuminuria will be compared between groups to provide preliminary efficacy testing.

    Time frame: 36 Weeks

  4. To perform preliminary efficacy testing and determine the variability of eGFR.

    Changes in eGFR will be compared between groups to provide preliminary efficacy testing. eGFR will be assessed using the CKD-Epi Formula.

    Time frame: 36 Weeks

Secondary outcomes

  1. Safety Monitoring: Body Weight

    Body weight will be measured using a digital scale accurate to +/- 0.1 kg at Screening, Week 0, Week 24, and Week 36. The investigator monitors changes in participants' body to detect any changes that may indicate treatment effects or safety concerns.

    Time frame: 36 Weeks

  2. EKG Evaluations

    An EKG will be performed at Screening, Week 0, Week 4, Week 16, Week 36, and Week 40. The investigators will be monitoring for new EKG changes suggestive of beta-adrenergic use such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, and/or serum potassium \<3.0 mEQ/L refractory to medical therapy.

    Time frame: 40 Weeks

  3. Adherence

    Adherence will be defined as the proportion of doses taken during the 36-week treatment period. For patients who fail to complete the study, adherence will be estimated as the number of doses they report taking for visits at which they are present over the total number of doses they should have received

    Time frame: 36 Weeks

  4. Adverse Events

    Rate of protocol related adverse events and serious adverse events will be compared between groups

    Time frame: 40 Weeks

  5. Tolerability and acceptability

    Intervention Tolerability: Participants will be asked every four weeks (Week 4-36) to rate on a 1-10 Likert scale how tolerable the intervention was over the past four weeks. Intervention Acceptability: Satisfaction with the intervention will be assessed every 4 weeks (Week 4-36) with a questionnaire that asks participants to rate on a 1-10 Likert scale how satisfied they were with specific domains of the intervention over the past 4 weeks. The major domains that will be assessed are satisfaction with: 1) how hard was it to adhere to prescribed treatment, and 2) how likely they feel they can adhere to the prescribed treatment for the next four weeks. Participants will also be asked in open-ended fashion to provide feedback on each domain of the intervention. The investigators will also assess intervention acceptability by comparing the frequency of protocol related adverse events, requirement for protocol modification, and attrition between groups.

    Time frame: 32 Weeks

  6. Liver Ultrasound Elastography

    non-invasive liver ultrasound elastography to determine if the patients had an improvement in liver steatosis with formoterol

    Time frame: 36 Weeks

  7. Laboratory Evaluations: HbA1c

    HbA1c assessments at Screening, Week 0, Week 16, Week 36, and Week 40 will be estimated and compared between and within groups.

    Time frame: 40 Weeks

  8. Laboratory Evaluations: CMP

    Comprehensive Metabolic Panel (CMP) (including hypokalemia assessments) at Screening, Week 0, Week 4, Week 12, Week 24, Week 36, and Week 40 will be estimated and compared between and within groups.

    Time frame: 40 Weeks

  9. Laboratory Evaluations: Urine Albumin

    Change in albuminuria between groups from baseline to the end of the study

    Time frame: 40 Weeks

  10. Laboratory Evaluations: eGFR

    Change in estimated glomerular filtration rate (eGFR, CKD-Epi eGFR formula) between groups from baseline to the end of the study

    Time frame: 40 Weeks

  11. Safety Monitoring: Heart Rate

    The investigator monitors changes in participants' heart rate throughout the trial to detect any changes that may indicate treatment effects or safety concerns.

    Time frame: 40 Weeks

  12. Safety Monitoring: Blood Pressure

    The investigator monitors changes in participants' blood pressure throughout the trial to detect any changes that may indicate treatment effects or safety concerns. Blood pressure (BP) will be measured with a sphygmomanometer (average of 2 seated values taken after five minutes of rest).

    Time frame: 40 Weeks

  13. Safety Monitoring: Respiratory Rate

    The investigator monitors changes in participants' respiratory rate throughout the trial to detect any changes that may indicate treatment effects or safety concerns.

    Time frame: 40 Weeks

  14. Safety Monitoring: Temperature

    The investigator monitors changes in participants' temperature throughout the trial to detect any changes that may indicate treatment effects or safety concerns.

    Time frame: 40 Weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
Jun 15, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Nov 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07022418
Collaborators
Dialysis Clinic, Inc.
Responsible party
Joshua Lipschutz (Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Jun 15, 2025
Start date
Dec 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Recruitment Contact
Contact
recruitment@musc.edu
(843) 792-0965
Joshua Lipschutz, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion